We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

22 hedge funds and large institutions have $3.17M invested in Moleculin Biotech in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more capital invested

Capital invested by funds: $3.16M → $3.17M (+$11.1K)

0% more ownership

Funds ownership: 0.03% → 0.03% (+0%)

8% less funds holding

Funds holding: 24 → 22 (-2)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
+$41.4K
2
VF
Virtu Financial
New York
+$15.6K
3
Citadel Advisors
Citadel Advisors
Florida
+$3.38K
4
CA
Clearstead Advisors
Ohio
+$844
5
UBS Group
UBS Group
Switzerland
+$844

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$21K
2
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$12K
3
BlackRock
BlackRock
New York
-$6.75K
4
TRCT
Tower Research Capital (TRC)
New York
-$5.07K
5
Osaic Holdings
Osaic Holdings
Arizona
-$3.38K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.14M +$422 +1 +0%
SCM
2
Sio Capital Management
New York
$1.1M – – –
BlackRock
3
BlackRock
New York
$272K -$6.75K -16 -2%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$261K -$844 -2 -0.3%
Renaissance Technologies
5
Renaissance Technologies
New York
$87K -$2.53K -6 -3%
State Street
6
State Street
Massachusetts
$75.7K – – –
SPC
7
Sigma Planning Corp
Michigan
$61K – – –
Northern Trust
8
Northern Trust
Illinois
$49.1K – – –
Charles Schwab
9
Charles Schwab
California
$38.8K +$41.4K +98 New
Citadel Advisors
10
Citadel Advisors
Florida
$17.5K +$3.38K +8 +22%
VF
11
Virtu Financial
New York
$15K +$15.6K +37 New
JE
12
JMAC Enterprises
Pennsylvania
$13.9K – – –
UBS Group
13
UBS Group
Switzerland
$11.9K +$844 +2 +7%
Bank of America
14
Bank of America
North Carolina
$7.08K – – –
Morgan Stanley
15
Morgan Stanley
New York
$6.72K +$422 +1 +6%
TRCT
16
Tower Research Capital (TRC)
New York
$6K -$5.07K -12 -46%
Osaic Holdings
17
Osaic Holdings
Arizona
$1.35K -$3.38K -8 -73%
Rockefeller Capital Management
18
Rockefeller Capital Management
New York
$1K – – –
CA
19
Clearstead Advisors
Ohio
$636 +$844 +2 New
Wells Fargo
20
Wells Fargo
California
$552 – – –
CFO
21
CVA Family Office
Colorado
$530 – – –
NSIM
22
North Star Investment Management
Illinois
$265 – – –
GRP
23
Global Retirement Partners
California
$178 – – –
Fidelity Investments
24
Fidelity Investments
Massachusetts
$2 – – –
Jane Street
25
Jane Street
New York
– -$21K -53 Closed
1
2

MBRX Hedge Fund Activity: Q4 2022 in Review

22 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2022, worth a combined $3.17M — up 0.35% from $3.16M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MBRX and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.

The largest buyer was Charles Schwab, opening a new position worth an estimated $41.4K. The largest seller was Jane Street, exiting entirely with an estimated $21K sold.

  • 22 institutional investors held Moleculin Biotech (MBRX) as of Q4 2022, down from 24 in Q3 2022.
  • Funds reported $3.17M of Moleculin Biotech stock for Q4 2022, up 0.35% quarter-over-quarter.
  • 3 funds opened new Moleculin Biotech positions in Q4 2022 and 4 closed out, a net change of -1 holder.
  • The largest Moleculin Biotech buyer in Q4 2022 was Charles Schwab, an estimated $41.4K added.
  • The largest Moleculin Biotech seller in Q4 2022 was Jane Street, an estimated $21K sold.

Based on aggregated 13F filings for Q4 2022.